Knowledge (XXG)

Pharmaceutical innovations

Source 📝

20:
2014 about $ 140 Billion is spent on research and development of pharmaceuticals which produces 25–35 new drugs annually. Technology, which is transforming science, medicine, and research tools has increased the speed at which we can analyze data but we currently still must test the products which is a lengthy process. Differences in the performance of medical care may be due to variation in the introduction and circulation of pharmaceutical innovations.
57:. The MPP aims to improve access to appropriate, affordable HIV medicines and technologies for people living with HIV in developing countries. Working in partnership with a range of stakeholders, the MPP opens the door to generic low-cost production of key HIV therapies as well as fixed-dose combinations and paediatric formulations by creating a pool of relevant patents for sub-licensing and product development. 336:? How many people could have been spared death by skin cancer if human breast milk could be used topically to eliminate cancerous cells? We cannot know. We just know that research and clinical trial money was not put into unpatentable targets at the same rate and volume that it was for patentable ones. 261:
As much money as has been put into HAMLET... it is remarkable that no money has been put into the use of actual Human Breast Milk as a medical product that could fight cancer. Again, Human Breast milk is not patentable, thus investing into clinical trials for its use as a medical product means that
19:
are currently guided by a patent system, the patent system protects the innovator of medicines for a period of time. The patent system does not currently stimulate innovation or pricing that provides access to medicine for those who need it the most, It provides for profitable innovation. As of
328:
It is impossible to quantify something that does not happen. We can count how much money got put into research by companies that rely on patents and we can estimate how much a process for a clinical trial costs, but it is impossible to define how much money SHOULD have been spent just like it is
247:
6) A patent for making HAMLET through combining alpha-lactalbumin with oleic acid was granted in 2008 (expired 2018). A patent for recombinant HAMLET was presented in 2010 (expires 2030). This can be viewed as HAMLET 2.0. Peptides for second generation use were patented in 2011. Use of HAMLET as
102:) is a proposed pay-for-performance mechanism that would provide a market-based solution to problems concerning the development and distribution of medicines globally. It would incentivize the research and development of new pharmaceutical products that make substantial reductions in the global 23:
Pharmaceutical innovation may not apply the same definition of "initiative" as other industries because while a product might use a new molecule or formula, that by itself holds very little value. For people that need the product the health benefits that were not previously achievable may be a
39:
The FDA has implemented the Breakthrough Therapy Designation which should help bring new needed products to the market faster.  One of the key concerns in the current patent system is that an innovation patent is overly generous given that it has a very low inventiveness threshold.
138:
for the patent holder. In health-care pharmaceuticals this advantage has proven to be highly profitable, driving over $ 83 billion dollars investment into Research and Development by the pharmaceutical industry in 2019. This focus on the profits of
289:
Research suggests that aloe gel, applied in the morning and evening in addition to the use of the topical prescription acne medicine tretinoin (Retin-A, Atralin, others), might be more effective in reducing acne than using a topical prescription
150:. These can be quite expensive, sometimes costing into the billions of dollars. That elevated cost makes it a bad investment to pay for a medicine to be approved that does not guarantee years of profits to those that put up the money. 298:
Aloe extract cream might reduce redness, scaling, itching and inflammation caused by mild to moderate psoriasis. You might need to use the cream several times a day for a month or more to see improvements in your
160:
ruled that isolation by itself is not sufficient for something to be deemed inventive subject matter, and thus patentable. As a rule, raw natural material is generally rejected for patent approval by the
265:
There are many naturally occurring plants and compounds that have medicinal properties. An example of a plant that holds multiple properties, but that has not had money put into clinical trials, is
964: 463:
Westerling, Ragnar; Westin, Marcus; McKee, Martin; Hoffmann, Rasmus; Plug, Iris; Rey, Grégoire; Jougla, Eric; Lang, Katrin; Pärna, Kersti; Alfonso, José L.; MacKenbach, Johan P. (2014).
793: 763: 1181:
Pettersson-Kastberg J, Aits S, Gustafsson L, Mossberg A, Storm P, Trulsson M, Persson F, Mok KH, Svanborg C (2009). "Can misfolded proteins be beneficial? The HAMLET case".
940: 657: 315:
Research suggests that twice-daily application of aloe gel for eight weeks might help reduce symptoms of this inflammatory condition that affects the inside of the mouth.
622: 375: 323:
Whether oral use of aloe latex is effective at treating constipation is unclear. While it acts as a laxative, aloe latex can also cause abdominal cramps and diarrhea.
24:
deciding factor as to whether or not it is initiative. While a pharmaceutical company may view a product that fills a niche as innovative if it can produce a profit.
187:
3) If the verified characteristic is deemed interesting, further experiments are made that attempt to isolate the compound that causes the interesting behavior.
437: 126:
An unintended but real consequence of the influence of a patent-heavy industry is that money is not put into unpatentable elements with the same fervor. A
708: 693: 332:
How much money could have been saved world-wide if doctors were allowed to prescribe medicine that many people can grow at home at a very low cost, like
281:
Application of aloe gel appears to shorten the duration of wound healing for first- and second-degree burns. Aloe gel might also promote wound healing.
162: 65:
Kristopher J. Hult has proposed a new measurement based on novel and incremental innovation. The model predicts a decline of 40% for the 2010s.
241:
5) Alpha-lactalbumin was partially unfolded to allow for release of the calcium ion and replacement with an oleic acid molecule, this enabled
189:
4) Once isolated, the compound is again subject to experimentation to verify that it is, indeed, the one that causes the interesting behavior.
554: 388: 894:
Dimasi, Joseph A; Grabowski, Henry G; Hansen, Ronald W (2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs".
771: 157: 248:
prophylaxis (preventive was) patented in 2013 (expires 2033). The use of HAMLET for Papilloma was patented in 2013 (expires 2023).
668: 213:
1) In 1995 Human Breast milk was observed that Human Breast Milk killed cancerous human cells while leaving healthy cells intact.
191:
5) In order to be able to patent, efforts are then made to try and modify the original substance in a way that differentiates it.
633: 394: 166: 734: 193:
6) Once the original substance has been successfully modified, a patent application is presented for the new substance.
84:
Regulatory uncertainty is one area that stifles innovation. The approval processes are becoming increasingly complex.
1286: 207: 345: 176: 69: 118:
economist Aidan Hollis, and is promoted by the non-profit organization Incentives for Global Health (IGH).
1291: 135: 115: 45: 579:
Scannell, JW; Blanckley, A; Boldon, H; Warrington, B (2012). "Eroom's Law in pharmaceutical R&D".
1094: 1006: 412: 130:
gives its owner the legal right to exclude others from making, using, or selling an invention for a
1140:
Gustafsson L, Hallgren O, Mossberg AK, Pettersson J, Fischer W, Aronsson A, Svanborg C (May 2005).
1250: 1206: 604: 94: 172:
The current patent structure lays incentives in a pattern that has been observed several times:
231:
4) In 2000 an active compound for tumericidal activity was found to be a complex that involved
146:
The process of having something be deemed usable as a medical product involves going through a
1198: 1163: 1122: 1034: 921: 851: 687: 596: 535: 494: 384: 236: 226: 153: 1190: 1153: 1112: 1102: 1024: 1014: 911: 903: 841: 833: 588: 525: 484: 476: 438:"MedidataVoice: The Next Wave Of Pharmaceutical Innovation: An Interview With Bernard Munos" 143:
leaves a downside where investment money is not going, that is, into unpatentable research.
350: 1098: 1010: 846: 821: 530: 513: 489: 464: 255: 251: 196: 147: 131: 103: 28: 465:"The timing of introduction of pharmaceutical innovations in seven European countries" 156:
are subject for debate and can vary from jurisdiction to jurisdiction. As of 2013 the
1280: 1117: 1082: 1029: 994: 140: 1210: 1142:"HAMLET kills tumor cells by apoptosis: structure, cellular mechanisms, and therapy" 709:"Medicines Patent Pool Aims To Increase Access To HIV Drugs In Developing Countries" 907: 608: 355: 242: 111: 1225: 195:
7) If the patent is granted the new pharmaceutical candidate can then be taken to
49:(MPP), is a United Nations-backed organisation founded in July 2010 and based in 742: 203: 76:
used the method to measure 2012 and found that the rate fell from 7.7% to 7.2%.
54: 993:
Håkansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C (August 1995).
1194: 232: 216: 182: 1158: 1141: 1019: 267: 222: 1202: 1167: 1126: 1107: 925: 855: 600: 539: 498: 329:
impossible to estimate the effect of a process that has not been realized.
1038: 941:"Gene Patents in Europe Relatively Stable Despite Uncertainty in the U.S." 72:, which is used to measure and compare the profitability of investments. 1081:
Svensson M, Håkansson A, Mossberg AK, Linse S, Svanborg C (April 2000).
965:"The Supreme Court Holds Genes Are Patent-Ineligible Products of Nature" 869: 837: 307:
Applying a cream containing aloe extract might help lesions heal sooner.
916: 73: 820:
Hollis, A; Grootendorst, P; Levine, DK; Pogge, T; Edwards, AM (2011).
480: 442: 127: 50: 1056: 592: 1083:"Conversion of alpha-lactalbumin to a protein inducing apoptosis" 107: 106:. The HIF is the creation of a team of researchers led by the 202:
An example of such an occurrence can be seen in the story of
179:
through observation on something that is naturally occurring.
274:"Research on the use of aloe for specific conditions shows: 208:
HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells)
794:"measuring the return from pharmaceutical innovation 2014" 764:"Measuring the return from pharmaceutical innovation 2012" 870:"Research and Development in the Pharmaceutical Industry" 27:
A decline in research and development has been coined as
822:"New approaches to rewarding pharmaceutical innovation" 219:
were made and the observed characteristic was verified.
555:"Is Pharmaceutical Productivity In Decline? Maybe Not" 512:
Morgan, Steven; Lopert, Ruth; Greyson, Devon (2008).
514:"Toward a definition of pharmaceutical innovation" 346:Pharmaceutical industry - The cost of innovation 250:7) HAMLET derived drug candidate, Alpha1H is in 739:University of Chicago - Department of Economics 185:are made to verify the observed characteristic. 988: 986: 984: 8: 995:"Apoptosis induced by a human milk protein" 229:(MAL) that caused the interesting behavior. 1050: 1048: 944:Genetic Engineering and Biotechnology News 469:Journal of Evaluation in Clinical Practice 1157: 1116: 1106: 1028: 1018: 915: 845: 529: 488: 163:United States Patent and Trademark Office 623:"Review of the Innovation Patent System" 122:Low investment into unpatentable options 431: 429: 367: 210:, the modified and patented variation. 692:: CS1 maint: archived copy as title ( 685: 377:Review of the Innovation Patent System 221:3) Further experiments were made that 175:1) Some interesting characteristic is 7: 826:Canadian Medical Association Journal 707:RUNYOWA, TAVENGWA (10 March 2011). 553:Feyman, Yevgeniy (13 April 2015). 411:Pogge, Thomas (18 December 2011), 245:and stabilization of the molecule. 169:have been patented several times. 68:One current way to measure is the 14: 1261:. Mayo Clinic. 17 September 2017 254:for use with patients that have 939:Sharples, Andrew (2011-03-23). 206:cancer killing properties and 908:10.1016/j.jhealeco.2016.01.012 735:"Kristopher J. Hult: Research" 167:genetically modified organisms 1: 581:Nature Reviews Drug Discovery 1087:Proc. Natl. Acad. Sci. U.S.A 999:Proc. Natl. Acad. Sci. U.S.A 896:Journal of Health Economics 414:Medicine for the 99 percent 1308: 17:Pharmaceutical innovations 1195:10.1080/07853890802502614 225:the compound multimeric 132:a limited period of time 1226:"About Clinical Trials" 1020:10.1073/pnas.92.17.8064 70:Internal rate of return 1108:10.1073/pnas.97.8.4221 262:profit cannot be had. 1159:10.1093/jn/135.5.1299 305:Herpes simplex virus. 136:competitive advantage 134:. This can provide a 116:University of Calgary 46:Medicines Patent Pool 1230:www.hamletpharma.com 1061:www.hamletpharma.com 1099:2000PNAS...97.4221S 1011:1995PNAS...92.8064H 838:10.1503/cmaj.100375 383:. 2014. p. 2. 313:Oral lichen planus. 204:Human Breast Milk's 733:Hult, Kristopher. 154:Biological patents 95:Health Impact Fund 801:www2.deloitte.com 481:10.1111/jep.12122 390:978-0-9804542-7-7 279:Burns and wounds. 237:alpha-lactalbumin 227:alpha-lactalbumin 104:burden of disease 1299: 1287:Drug development 1271: 1270: 1268: 1266: 1247: 1241: 1240: 1238: 1236: 1221: 1215: 1214: 1178: 1172: 1171: 1161: 1137: 1131: 1130: 1120: 1110: 1078: 1072: 1071: 1069: 1067: 1052: 1043: 1042: 1032: 1022: 990: 979: 978: 976: 974: 969: 963:Sheehan, Teige. 960: 954: 953: 951: 950: 936: 930: 929: 919: 891: 885: 884: 882: 881: 866: 860: 859: 849: 817: 811: 810: 808: 807: 798: 790: 784: 783: 781: 779: 774:on 16 April 2015 770:. Archived from 760: 754: 753: 751: 750: 741:. Archived from 730: 724: 723: 721: 719: 704: 698: 697: 691: 683: 681: 679: 674:on 23 April 2010 673: 667:. Archived from 662: 654: 648: 647: 645: 644: 638: 632:. Archived from 627: 619: 613: 612: 576: 570: 569: 567: 565: 550: 544: 543: 533: 509: 503: 502: 492: 460: 454: 453: 451: 450: 436:Milet, Sylvain. 433: 424: 423: 422: 421: 408: 402: 401: 399: 393:. Archived from 382: 372: 158:US Supreme Court 1307: 1306: 1302: 1301: 1300: 1298: 1297: 1296: 1277: 1276: 1275: 1274: 1264: 1262: 1249: 1248: 1244: 1234: 1232: 1224:HAMLET PHARMA. 1223: 1222: 1218: 1180: 1179: 1175: 1152:(5): 1299–303. 1139: 1138: 1134: 1080: 1079: 1075: 1065: 1063: 1055:HAMLET PHARMA. 1054: 1053: 1046: 992: 991: 982: 972: 970: 967: 962: 961: 957: 948: 946: 938: 937: 933: 893: 892: 888: 879: 877: 868: 867: 863: 819: 818: 814: 805: 803: 796: 792: 791: 787: 777: 775: 762: 761: 757: 748: 746: 732: 731: 727: 717: 715: 706: 705: 701: 684: 677: 675: 671: 660: 658:"Archived copy" 656: 655: 651: 642: 640: 636: 630:www.acip.gov.au 625: 621: 620: 616: 593:10.1038/nrd3681 578: 577: 573: 563: 561: 552: 551: 547: 511: 510: 506: 462: 461: 457: 448: 446: 435: 434: 427: 419: 417: 410: 409: 405: 397: 391: 380: 374: 373: 369: 364: 351:Chemical patent 342: 252:clinical trials 249: 246: 240: 230: 220: 214: 197:clinical trials 194: 192: 190: 188: 186: 180: 124: 90: 88:Proposed models 82: 63: 37: 12: 11: 5: 1305: 1303: 1295: 1294: 1289: 1279: 1278: 1273: 1272: 1242: 1216: 1173: 1132: 1073: 1044: 1005:(17): 8064–8. 980: 955: 931: 886: 876:. 8 April 2021 861: 812: 785: 755: 725: 699: 665:www.unitaid.eu 649: 614: 587:(3): 191–200. 571: 545: 504: 475:(4): 301–310. 455: 425: 403: 400:on 2015-02-27. 389: 366: 365: 363: 360: 359: 358: 353: 348: 341: 338: 256:bladder cancer 148:clinical trial 123: 120: 89: 86: 81: 78: 62: 59: 36: 33: 13: 10: 9: 6: 4: 3: 2: 1304: 1293: 1292:Patent reform 1290: 1288: 1285: 1284: 1282: 1260: 1258: 1254: 1246: 1243: 1231: 1227: 1220: 1217: 1212: 1208: 1204: 1200: 1196: 1192: 1189:(3): 162–76. 1188: 1184: 1177: 1174: 1169: 1165: 1160: 1155: 1151: 1147: 1143: 1136: 1133: 1128: 1124: 1119: 1114: 1109: 1104: 1100: 1096: 1093:(8): 4221–6. 1092: 1088: 1084: 1077: 1074: 1062: 1058: 1051: 1049: 1045: 1040: 1036: 1031: 1026: 1021: 1016: 1012: 1008: 1004: 1000: 996: 989: 987: 985: 981: 966: 959: 956: 945: 942: 935: 932: 927: 923: 918: 913: 909: 905: 901: 897: 890: 887: 875: 871: 865: 862: 857: 853: 848: 843: 839: 835: 831: 827: 823: 816: 813: 802: 795: 789: 786: 773: 769: 765: 759: 756: 745:on 2015-04-16 744: 740: 736: 729: 726: 714: 710: 703: 700: 695: 689: 670: 666: 659: 653: 650: 639:on 2015-02-27 635: 631: 624: 618: 615: 610: 606: 602: 598: 594: 590: 586: 582: 575: 572: 560: 556: 549: 546: 541: 537: 532: 527: 523: 519: 515: 508: 505: 500: 496: 491: 486: 482: 478: 474: 470: 466: 459: 456: 445: 444: 439: 432: 430: 426: 416: 415: 407: 404: 396: 392: 386: 379: 378: 371: 368: 361: 357: 354: 352: 349: 347: 344: 343: 339: 337: 335: 330: 326: 324: 322: 321:Constipation. 317: 316: 314: 309: 308: 306: 301: 300: 297: 292: 291: 288: 283: 282: 280: 275: 272: 270: 269: 263: 259: 257: 253: 244: 238: 235:. as well as 234: 228: 224: 218: 211: 209: 205: 200: 198: 184: 178: 173: 170: 168: 164: 159: 155: 151: 149: 144: 142: 141:patentability 137: 133: 129: 121: 119: 117: 113: 109: 105: 101: 97: 96: 87: 85: 79: 77: 75: 71: 66: 60: 58: 56: 52: 48: 47: 41: 35:Current model 34: 32: 30: 25: 21: 18: 1263:. Retrieved 1256: 1252: 1245: 1233:. Retrieved 1229: 1219: 1186: 1182: 1176: 1149: 1145: 1135: 1090: 1086: 1076: 1064:. Retrieved 1060: 1002: 998: 971:. Retrieved 958: 947:. Retrieved 943: 934: 899: 895: 889: 878:. Retrieved 873: 864: 832:(6): 681–5. 829: 825: 815: 804:. Retrieved 800: 788: 776:. Retrieved 772:the original 767: 758: 747:. Retrieved 743:the original 738: 728: 716:. Retrieved 712: 702: 676:. Retrieved 669:the original 664: 652: 641:. Retrieved 634:the original 629: 617: 584: 580: 574: 562:. Retrieved 558: 548: 521: 517: 507: 472: 468: 458: 447:. Retrieved 441: 418:, retrieved 413: 406: 395:the original 376: 370: 356:Generic drug 333: 331: 327: 320: 319: 318: 312: 311: 310: 304: 303: 302: 295: 294: 293: 286: 285: 284: 278: 277: 276: 273: 266: 264: 260: 243:cytotoxicity 212: 201: 174: 171: 152: 145: 125: 112:Thomas Pogge 110:philosopher 99: 93: 91: 83: 67: 64: 44: 42: 38: 26: 22: 16: 15: 917:10161/12742 874:www.cbo.gov 524:(1): e4–7. 217:Experiments 183:Experiments 61:Measurement 55:Switzerland 29:Eroom's Law 1281:Categories 1265:21 January 949:2013-06-13 880:2022-01-13 806:2015-04-15 749:2015-04-16 678:25 January 643:2015-04-15 449:2015-04-15 420:2015-04-15 362:References 296:Psoriasis. 233:oleic acid 177:discovered 1257:Aloe vera 1057:"Patents" 902:: 20–33. 334:Aloe vera 268:Aloe vera 1211:31198109 1203:18985467 1183:Ann. Med 1168:15867328 1127:10760289 926:26928437 856:21149519 778:16 April 713:IP Watch 688:cite web 601:22378269 564:16 April 540:21602949 518:Open Med 499:24750393 340:See also 223:isolated 114:and the 80:Barriers 1146:J. Nutr 1095:Bibcode 1039:7644538 1007:Bibcode 973:20 June 847:3071389 768:Reuters 609:3344476 531:3091590 490:4282430 74:Reuters 1235:13 Jan 1209:  1201:  1166:  1125:  1115:  1066:13 Jan 1037:  1027:  924:  854:  844:  718:2 June 607:  599:  559:Forbes 538:  528:  497:  487:  443:Forbes 387:  290:alone. 165:, but 128:patent 51:Geneva 1207:S2CID 1118:18203 1030:41287 968:(PDF) 797:(PDF) 672:(PDF) 661:(PDF) 637:(PDF) 626:(PDF) 605:S2CID 398:(PDF) 381:(PDF) 299:skin. 287:Acne. 1267:2020 1253:Aloe 1237:2022 1199:PMID 1164:PMID 1123:PMID 1068:2022 1035:PMID 975:2020 922:PMID 852:PMID 780:2015 720:2015 694:link 680:2022 597:PMID 566:2015 536:PMID 495:PMID 385:ISBN 108:Yale 92:The 43:The 1191:doi 1154:doi 1150:135 1113:PMC 1103:doi 1025:PMC 1015:doi 912:hdl 904:doi 842:PMC 834:doi 830:183 589:doi 526:PMC 485:PMC 477:doi 215:2) 181:2) 100:HIF 1283:: 1259:)" 1228:. 1205:. 1197:. 1187:41 1185:. 1162:. 1148:. 1144:. 1121:. 1111:. 1101:. 1091:97 1089:. 1085:. 1059:. 1047:^ 1033:. 1023:. 1013:. 1003:92 1001:. 997:. 983:^ 920:. 910:. 900:47 898:. 872:. 850:. 840:. 828:. 824:. 799:. 766:. 737:. 711:. 690:}} 686:{{ 663:. 628:. 603:. 595:. 585:11 583:. 557:. 534:. 520:. 516:. 493:. 483:. 473:20 471:. 467:. 440:. 428:^ 325:" 271:. 258:. 199:. 53:, 31:. 1269:. 1255:( 1251:" 1239:. 1213:. 1193:: 1170:. 1156:: 1129:. 1105:: 1097:: 1070:. 1041:. 1017:: 1009:: 977:. 952:. 928:. 914:: 906:: 883:. 858:. 836:: 809:. 782:. 752:. 722:. 696:) 682:. 646:. 611:. 591:: 568:. 542:. 522:2 501:. 479:: 452:. 239:. 98:(

Index

Eroom's Law
Medicines Patent Pool
Geneva
Switzerland
Internal rate of return
Reuters
Health Impact Fund
burden of disease
Yale
Thomas Pogge
University of Calgary
patent
a limited period of time
competitive advantage
patentability
clinical trial
Biological patents
US Supreme Court
United States Patent and Trademark Office
genetically modified organisms
discovered
Experiments
clinical trials
Human Breast Milk's
HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells)
Experiments
isolated
alpha-lactalbumin
oleic acid
alpha-lactalbumin

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.